In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023.
According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery.
Check out the Evaluate team’s thoughts on the top-selling drugs, biggest companies, biggest launches, most promising R&D projects and predictions on topics like regulation, the stock market, IPOs, and venture funding.
You can also share your own predictions for 2023 with the Evaluate team using this poll.
Download the full report here.